A major historical limitation of conduction system pacing (CSP) has been the inability to deliver physiological pacing directly through a defibrillation lead. Patients with an indication for an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) who required left bundle branch area pacing (LBBAP) previously necessitated a "two-lead" approach. This involved positioning a specialized, thin pacing lead (such as the SelectSecure 3830) in the left bundle branch region, alongside a conventional thick defibrillation lead at the right ventricular apex. This approach significantly increased intra-cardiac hardware volume, elevated the risk of venous occlusion, and introduced potential lead-to-lead interactions.
This clinical challenge has been definitively resolved by a major technological breakthrough:
Key Innovations and Clinical Evidence
- FDA Approval of OmniaSecure™ for LBBAP (March 23, 2026): The FDA issued a landmark, expanded indication for the OmniaSecure™ defibrillation lead, making it the first and only defibrillation lead globally officially indicated for placement in the left bundle branch area (LBB area) to achieve physiological pacing.
- Lumenless Design & Ultra-Low Profile: Disrupting traditional ICD lead dimensions, the OmniaSecure™ features a lumenless design with a diameter of just 4.7 French (1.66 mm), making it the smallest defibrillation lead on the global market. Its ultra-thin profile mirrors that of a standard bradycardia pacing lead, allowing the operator to steer and torque the lead deeply into the interventricular septum via a trans-interventricular septal pacing technique without inducing significant trauma or perforation.
- The LEADR Global Clinical Trial [1]: Primary clinical data supporting this approval demonstrated excellent performance of the OmniaSecure™ lead within the left bundle branch area:
- 100% Defibrillation Efficacy: Successful termination of ventricular tachycardia/fibrillation (VT/VF) was confirmed at implantation, proving that subendocardial/septal deployment does not compromise the delivery of life-saving shock therapy.
- High Structural Reliability: The study recorded zero lead fractures and exceptionally stable electrical parameters, including low pacing thresholds and excellent R-wave sensing, at one year.
Clinical Implications for Device Upgrades and LOT-CRT
This lead radically transforms heart failure management. It enables the delivery of both physiological pacing and defibrillation protection through a single lead. Furthermore, it simplifies the Left Bundle Branch Optimized CRT (LOT-CRT) strategy by combining ICD and LBBAP functions into a single header port. This leaves the coronary sinus port available for an additional epicardial left ventricular lead if required, without overloading the patient’s venous anatomy.
References
- Crossley GH, Sanders P, Hansky B, De Filippo P, Shah MJ, Khelae SK, Richardson TD, Philippon F, Zakaib JS, Geelen T, Arias K, Maus B, Mason PK; Lead EvaluAtion for Defibrillation and Reliability Trial Investigators. Safety and Efficacy of the Novel OmniaSecure Defibrillation Lead Through Long-Term Follow-Up: Final Results From the LEADR Trial. Circ Arrhythm Electrophysiol. 2026 Jan;19(1):e014424. doi: 10.1161/CIRCEP.125.014424. Epub 2025 Nov 12. PMID: 41222500; PMCID: PMC12822760.
References
- Crossley GH, Sanders P, Hansky B, De Filippo P, Shah MJ, Khelae SK, Richardson TD, Philippon F, Zakaib JS, Geelen T, Arias K, Maus B, Mason PK; Lead EvaluAtion for Defibrillation and Reliability Trial Investigators. Safety and Efficacy of the Novel OmniaSecure Defibrillation Lead Through Long-Term Follow-Up: Final Results From the LEADR Trial. Circ Arrhythm Electrophysiol. 2026 Jan;19(1):e014424. doi: 10.1161/CIRCEP.125.014424. Epub 2025 Nov 12. PMID: 41222500; PMCID: PMC12822760.